
    
      Describe the safety of maintenance dasatinib, 100 mg/day for 2 years, in patients with stage
      III NSCLC.

      For patients with potentially resectable disease, to assess the pathologic complete response
      following neoadjuvant dasatinib, paclitaxel, carboplatin and 50.4 Gy concurrent radiation.

      For patients with locally unresectable disease, to obtain radiographic response data
      following dasatinib, paclitaxel, carboplatin and 64.8 Gy radiation.
    
  